MedPacto, Inc.
Financials
Valuation Metrics
MedPacto, Inc.'s Market Cap is ₩1217B. At end of 2025 it was ₩2290B. Ranked #1098 of 2,405 in KR market (top 46%), #567 of 1,627 on KOSDAQ (top 35%), #128 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 55%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 121.68B KRW | KR#1,098/2,405 Sec#128/231 |
| Revenue | 4.99B KRW | KR#2,328/2,405 Sec#196/231 |
| Net Income | -14.14B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 48.66B KRW | KR#2,212/2,405 Sec#204/231 |
| Net Assets | 45.98B KRW | KR#1,955/2,405 Sec#167/231 |
| Employees | 57 | KR#1,979/2,405 Sec#177/231 |
| Value | ||
| P/B | 2.65x | KR#2,095/2,405 Sec#163/231 |
| P/S | 24.36x | KR#2,337/2,405 Sec#189/231 |
| FCF Yield | -11.08% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | -30.75% | KR#2,179/2,405 Sec#176/231 |
| ROA | -29.06% | KR#2,298/2,405 Sec#201/231 |
| Op. Margin | -309.63% | KR#2,332/2,405 Sec#195/231 |
| Revenue Growth | 293.41% | KR#20/2,405 Sec#6/231 |
| Financial Health | ||
| Debt Ratio | 5.83% | KR#44/2,405 Sec#13/231 |
| Total Debt | 0 KRW | KR—/2,405 Sec—/231 |
| FCF | -13.48B KRW | KR#1,786/2,405 Sec#163/231 |
| Cash | 12.00B KRW | KR#1,581/2,405 Sec#133/231 |
| Current Ratio | 23.06x | KR#19/2,405 Sec#8/231 |
| Performance | ||
| 1Y Return | -18.20% | KR#1,274/2,405 Sec#95/231 |
| 1M Return | 19.53% | KR#54/2,405 Sec#3/231 |
| From 52W High | -58.96% | KR#1,617/2,405 Sec#134/231 |
| 1Y MDD | -72.17% | KR#2,048/2,405 Sec#177/231 |
| Trading | ||
| Volume | 438,388 shares | KR#179/2,405 Sec#10/231 |
| Trading Value | 1.52B KRW | KR#484/2,405 Sec#46/231 |
| Foreign Own. | 4.42% | KR#963/2,405 Sec#84/231 |
| Per Share | ||
| EPS | -413 KRW | KR—/2,405 Sec—/231 |
| BPS | 1,342 KRW | KR#2,230/2,405 Sec#198/231 |
Company Info
The company, a bio company that spun off from Theragen Etex in 2013, was listed on the KOSDAQ market in 2019 as a technology growth company. It develops innovative new drugs for treating intractable cancer and chronic diseases, and discovers new drug candidate targets using advanced genome analysis technologies like next-generation sequencing and bioinformatics. Its flagship Baektoseoptip is under co-development for combination therapy with MSD and AstraZeneca. The company pursues precision medicine innovation with customized therapeutics and MA-B2 target antibody therapeutics. MedPacto, established in 2013, is headquartered in Seocho District, Seoul Metropolitan City.